Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

HelixNano

company

About

Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases.

Details

Last Funding Type
Convertable Note
Last Funding Money Raised
$10M
Industries
Artificial Intelligence,Biotechnology,Genetics,Health Care
Founded date
Jan 1, 2013
Number Of Employee
1 - 10
Operating Status
Active

Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases. HelixNano is a Y Combinator and venture backed biotech startup. At HelixNano, we have spent the last two years developing cancer vaccines. Now we are adapting our synthetic biology arsenal to take on COVID-19. We’re moving fast but thinking long-term. We’re already testing COVID-19 vaccine candidates designed to be precise and safe. Our next goal is to create a vaccine that protects everyone not only from this virus, but all future coronaviruses.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
29
$60.30M
HelixNano has raised a total of $60.30M in funding over 2 rounds. Their latest funding was raised on Sep 5, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 5, 2022 Series A 1 Detail
Mar 22, 2022 Series A $45M 3 Milano Investment Partners SGR Detail
Jan 1, 2022 Convertable Note $10M 1 Alameda Research Detail
Sep 30, 2021 Series A 1 Detail
Mar 20, 2020 Convertable Note $110K 3 Detail

Employee Profiles

Number of Employee Profiles
9
HelixNano has 9 current employee profiles, including Executive Hannu Rajaniemi
Executive
Executive
Employee
Employee